Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33846712.
- Also identified by DOI 10.1093/cid/ciab302.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.
Medical subject headings
- Hepatitis B
- Multiple Myeloma